COSM

Cosmos Health ($COSM) CEO Accumulates Over $1 Million in Shares During 4-Month Buying Spree Despite Stock Decline

04/24/2025 02:01

Cosmos Health's CEO continues to make substantial stock purchases despite the company's declining share price, drawing significant investor attention. Shares of $COSM have been on a consistent downtrend, trading at $0.40 as of April 23, 2025, representing a roughly 47% decline over the past six months. The stock steadily fell from early 2025 through March, reaching as low as $0.32 before a slight recent recovery. Despite this price deterioration, Cosmos Health's CEO Grigorios Siokas has consistently purchased company shares from December 2024 through April 2025. Notably, Siokas has demonstrated a pattern of increasing the size of his purchases as the stock price drops lower. Most recently, on April 21 and 22, 2025, Siokas acquired 654,912 shares (worth $208,000) and 175,000 shares (worth $63,000), respectively. These substantial purchases occurred when the stock was trading near its 52-week low at $0.32 and $0.36. Previously, Siokas bought 354,296 shares (worth $200,000) on February 24, 2025, and another 218,286 shares (approximately $110,000) in early March. Cosmos Health's CFO Georgios Terzis also purchased 85,778 shares (worth $50,000) on December 20, 2024. This consistent buying pattern among key executives suggests insiders believe the current stock price significantly undervalues the company. Cosmos Health manufactures and distributes pharmaceuticals, nutraceuticals, and CBD products. In July 2024, the company secured a contract manufacturing agreement with Australian firm Humacology to produce up to 500,000 CBD units annually. Additionally, in August 2024, the company announced the positive news that it had regained full compliance with Nasdaq listing requirements. However, the company has struggled financially. In August 2024, Cosmos reported a quarterly loss of $0.15 per share, and in November, it reported an even larger loss of $0.45 per share, significantly worse than analysts' expectations of an $0.11 loss. Revenue also fell short at $12.41 million compared to the expected $14.00 million. Cosmos Health, a small-cap company with a market capitalization of approximately $8 million, faces challenging circumstances. However, the CEO's persistent and substantial stock purchases signal strong management confidence in the company's long-term growth potential. The timing of these purchases at near-bottom prices is particularly noteworthy. Analysts maintain a 'buy' rating on $COSM with a median 12-month price target of $4.00, suggesting a potential upside of approximately 900% from current levels. However, investors should recognize the inherent volatility and higher investment risk associated with small-cap stocks. If performance improvements and increased revenues from the Humacology contract materialize in the coming months, the insiders' confidence may be justified. Investors should monitor both the strong insider buying signals and potential performance improvements closely.

You can receive notifications when news is published.